Ironwood Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Ironwood Pharmaceuticals has a total shareholder equity of $-346.3M and total debt of $697.9M, which brings its debt-to-equity ratio to -201.5%. Its total assets and total liabilities are $471.1M and $817.4M respectively. Ironwood Pharmaceuticals's EBIT is $168.3M making its interest coverage ratio 63.3. It has cash and short-term investments of $92.2M.
Key information
-201.5%
Debt to equity ratio
US$697.87m
Debt
| Interest coverage ratio | 63.3x |
| Cash | US$92.15m |
| Equity | -US$346.29m |
| Total liabilities | US$817.37m |
| Total assets | US$471.07m |
Recent financial health updates
Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Jun 22Recent updates
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 16Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Jan 31Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price
Dec 19Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued
Apr 18Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Oct 05These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh
Jul 29Ironwood Pharmaceuticals: Undervalued Company With Steady Growth
Sep 27Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today
Jul 21Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Jun 22Ironwood Pharmaceuticals names Thomas McCourt permanent CEO
Jun 07Financial Position Analysis
Short Term Liabilities: IRWD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: IRWD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: IRWD has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: IRWD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable IRWD has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: IRWD is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 45.8% per year.